HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Biochemical markers in persons with preclinical familial Alzheimer disease.

AbstractBACKGROUND:
Persons at risk for familial Alzheimer disease (FAD) provide a model in which biomarkers can be studied in presymptomatic disease.
METHODS:
Twenty-one subjects at risk for presenilin-1 (n = 17) or amyloid precursor protein (n = 4) mutations underwent evaluation with the Clinical Dementia Rating (CDR) scale. We obtained plasma from all subjects and CSF from 11. Plasma (Abeta(40), Abeta(42), F(2)-isoprostanes) and CSF (F(2)-isoprostanes, t-tau, p-tau(181), Abeta(40), Abeta(42), and Abeta(42)/Abeta(40) ratio) levels were compared between FAD mutation carriers (MCs) and noncarriers (NCs).
RESULTS:
Plasma Abeta(42) levels (25.1 pM vs 15.5 pM, p = 0.031) and the ratio of Abeta(42)/Abeta(40) (0.16 vs 0.11, p = 0.045) were higher in presymptomatic MCs. Among MCs, those with CDR scores of 0.5 had lower plasma Abeta(42) levels than those with CDR scores of 0 (14.1 pM vs 25.1, p = 0.02). The ratio of Abeta(42) to Abeta(40) was also reduced in the CSF (0.08 vs 0.15, p = 0.046) of nondemented MCs compared to NCs. Total CSF tau and p-tau(181) levels were elevated in presymptomatic FAD MCs. CSF levels of F(2)-isoprostanes were also elevated in MCs (n = 7, 48.6 pg/mL) compared to NCs (n = 4, 21.6 pg/mL, p = 0.031).
CONCLUSIONS:
Our data indicate that Abeta(42) is elevated in plasma in familial Alzheimer disease (FAD) mutation carriers (MCs) and suggests that this level may decrease with disease progression prior to the development of overt dementia. We also demonstrated that the ratio of Abeta(42) to Abeta(40) was reduced in the CSF of nondemented MCs and that elevations of t-tau and p-tau(181) are sensitive indicators of presymptomatic disease. Our finding of elevated F(2)-isoprostane levels in the CSF of preclinical FAD MCs suggests that oxidative stress occurs downstream to mismetabolism of amyloid precursor protein.
AuthorsJ M Ringman, S G Younkin, D Pratico, W Seltzer, G M Cole, D H Geschwind, Y Rodriguez-Agudelo, B Schaffer, J Fein, S Sokolow, E R Rosario, K H Gylys, A Varpetian, L D Medina, J L Cummings
JournalNeurology (Neurology) Vol. 71 Issue 2 Pg. 85-92 (Jul 08 2008) ISSN: 1526-632X [Electronic] United States
PMID18509095 (Publication Type: Journal Article)
Chemical References
  • APLP1 protein, human
  • Amyloid beta-Protein Precursor
  • Biomarkers
  • Isoprostanes
  • PSEN1 protein, human
  • Presenilin-1
  • Protease Nexins
  • Receptors, Cell Surface
  • tau Proteins
Topics
  • Adult
  • Alzheimer Disease (blood, cerebrospinal fluid, diagnosis, genetics, prevention & control)
  • Amyloid beta-Protein Precursor (genetics)
  • Biomarkers (blood, cerebrospinal fluid)
  • Female
  • Heterozygote
  • Humans
  • Isoprostanes (blood, cerebrospinal fluid)
  • Male
  • Mutation
  • Neurologic Examination
  • Presenilin-1 (genetics)
  • Protease Nexins
  • Receptors, Cell Surface (genetics)
  • Sensitivity and Specificity
  • tau Proteins (cerebrospinal fluid)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: